Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Remedief pain management supplement launching in food, drug and mass outlets nationwide in September, positioned on OTC shelves to compete with pain relievers such as Tylenol and Advil, firm announces June 22. Product contains 160 mg white willow, 100 mg kava, 75 mg boswellia and 75 mg Nexrutine, a proprietary COX-II inhibitor manufactured by Irvine, Calif.-based Next Pharmaceuticals. Remedief delivers "natural relief of pain associated with tension, stress and overexertion," Natrol says. Directions advise one-a-day dose and suggest consumers not take more than five capsules in 24 hours; 20 capsules carry a suggested retail price of $6.99. Print ads slated to debut in late September

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts